格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究*

doi:10.3969/j.issn.1672-5069.2023.06.009

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 801-804.doi: 10.3969/j.issn.1672-5069.2023.06.009

格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*

曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂

646000 四川省泸州市西南医科大学附属医院感染病科(曹汴川,黄富礼,黄永茂);四川省凉山彝族自治州越西县第一人民医院抗病毒治疗中心(刘梅,丁苹,汤玲毓,郭明贤,周仙,袁天茹);四川省德阳市第六人民医院药剂科(严一凯)

收稿日期:2023-03-07 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 黄永茂,E-mail: huang5616@sina.com
作者简介:曹汴川,男,36岁,医学博士,主治医师。E-mail: tccbc2016@swmu.edu.cn
基金资助:
^* 四川省科技厅科研课题(编号:2020YFS0514)

Efficacy and safety of glecaprevir/pibrentasvir in treating patients with HCV mono-infection and HIV/HCV co-infection

Cao Bianchuan, Liu Mei, Ding Ping, et al

Department of Infectious Diseases, Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan Province, China

Received:2023-03-07 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

摘要： 目的评估应用格卡瑞韦/哌仑他韦治疗丙型肝炎病毒(HCV)感染和人类免疫缺陷病毒(HIV)合并HCV感染者的疗效及安全性。方法 2021年4月～2021年12月凉山彝族自治州越西县第一人民医院诊治的HCV感染者25例和HIV合并HCV感染者27例,均接受格卡瑞韦/哌仑他韦治疗8～12周,随访12周。结果两组静脉注射毒品感染HCV的比率分别为60.0%和63.0%;HCV感染者实现持续病毒学应答(SVR)为92.0%,而HIV合并HCV感染者为88.9%,两组间差异无统计学意义(P=1.000);两组患者对该药耐受性良好,均未发生不良事件导致的治疗方案调整或中止。结论应用格卡瑞韦/哌仑他韦治疗HCV感染者和HIV合并HCV感染者具有较好的近期疗效和较高的安全性。

关键词: 丙型肝炎病毒, 艾滋病, 混合感染, 直接抗病毒药物, 格卡瑞韦/哌仑他韦, 治疗, 安全性

Abstract: Objective This clinical trial was conducted to evaluate the efficacy and safety of glecaprevir/pibrentasvir in treatment of patients with HCV mono-infection and HIV/HCV co-infection. Methods 25 patients with hepatitis C virus infection, including chronic hepatitis C (CHC) in 22 cases and compensated liver cirrhosis (CLC) in 3 cases, and 27 patients with HIV and HCV co-infection, including CHC in 25 cases and CLC in 2 cases, were enrolled in this study between April 2021 and December 2021, and all received glecaprevir/pibrentasvir antiviral therapy for eight to twelve weeks. All patients were followed-up for 12 weeks. Results The percentages of intravenous drug users in the two groups were 60.0% and 63.0%; the sustained virological response (SVR) at 12 weeks after treatment(SVR 12) in patients with HCV infection was 92.0%, not significantly different compared to 88.9% (P=1.000) in patients with HIV/HCV co-infection; the glecaprevir/pibrentasvir therapy was well tolerated in the two groups, and there was no severe adverse events leading to the adjustment or suspension of the anti-viral therapy regimen. Conclusion The administration of glecaprevir/pibrentasvir anti-viral therapy has a promising short-term efficacy and safety in the treatment of patients with HCV mono-infection and HIV/HCV co-infection.

Key words: Hepatitis C virus, AIDS, Co-infection, Direct antiviral agents, Glecaprevir/pibrentasvir, Therapy, Safety

曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.

Cao Bianchuan, Liu Mei, Ding Ping, et al. Efficacy and safety of glecaprevir/pibrentasvir in treating patients with HCV mono-infection and HIV/HCV co-infection[J]. Journal of Practical Hepatology, 2023, 26(6): 801-804.

参考文献

[1] Yin Y, Yang H, Xie X, et al. Status and associated characteristics of HIV disclosure among people living with HIV/AIDS in Liangshan, China: A cross-sectional study. Medicine (Baltimore),2019,98(31):e16681.
[2] Wang H, Chen A C, Wan S, et al. Status and associated factors of self-management in people living with HIV/AIDS in Liangshan area, China: a cross-sectional study. Patient Prefer Adherence,2019,13:863-870.
[3] Chen L, Liu C H, Kang S, et al. Determinants of suboptimal immune recovery among a Chinese Yi ethnicity population with sustained HIV suppression. BMC Infect Dis,2022,22(1):137.
[4] Chen L, Du L, Kang S, et al. Sofosbuvir plus ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep,2021,11(1):11301.
[5] Westerhoff M, Ahn J. Chronic hepatitis C and direct acting antivirals. Surg Pathol Clin,2018,11(2):287-296.
[6] 包飞云,李彤,王玉珊,等. 索磷布韦维帕他韦治疗慢性丙型肝炎患者疗效和安全性观察:一项单中心真实世界回顾性分析. 实用肝脏病杂志,2022,25(1):30-33.
[7] Howe A, Rodrigo C, Cunningham E B, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep,2022,4(5):100462.
[8] 魏来,段钟平,王贵强. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23(1):33-52.
[9] Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization,2018. https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/.
[10] Lamb Y N. Glecaprevir/pibrentasvir: First global approval. Drugs,2017,77(16):1797-1804.
[11] Hu S, Yuan F, Feng L, et al. KIR2DL2/C1 is a risk factor for chronic infection and associated with non-response to PEG-IFN and RBV combination therapy in hepatitis C virus genotype 1b patients in China. Virol Sin,2018,33(4):369-372.
[12] 胡春霞,杨娇楠,张丰晓,等. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析. 实用肝脏病杂志,2022,25(3):359-362.
[13] Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology,2018,155(2):411-421.
[14] Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med,2002,347(13):975-982.
[15] WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization, 2016, https://www.who.int/
[16] Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology,2005,42(4):962-973.
[17] Xiang Y, Lai X F, Chen P, et al. The correlation of HCV RNA and HCV core antigen in different genotypes of HCV. J Clin Lab Anal,2019,33(1):e22632.
[18] Huang K, Chen J, Xu R, et al. Molecular evolution of hepatitis C virus in China: A nationwide study. Virology,2018,516:210-218.
[19] 李杰,陈杰,庄辉. 丙型肝炎的流行病学. 实用肝脏病杂志,2012,15(5):379-381.
[20] Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol,2018,53(4):557-565.

格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*

Efficacy and safety of glecaprevir/pibrentasvir in treating patients with HCV mono-infection and HIV/HCV co-infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[6]	陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.
[7]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[8]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[9]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[10]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[11]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[12]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[13]	青秀, 周沙, 刘斌. HIFU消融联合化疗治疗中晚期肝母细胞瘤小儿5年随访研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 911-914.
[14]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.
[15]	古乾权, 陈杰, 邓开. 双镜联合治疗胆囊结石合并肝外胆管结石患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 919-922.